Orhan İnCe
Orhan İnCe has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ertuğrul Okuyan
Istanbul Medipol Üniversitesi
5 shared publications - Sevgi Özcan
Department of Cardiology, Bagcılar Training and Research Hospital, İstanbul, Türkiye
3 shared publications - Esra Dönmez
Department of Cardiology, Bagcilar Training and Research Hospital, Istanbul, Turkey
2 shared publications - İrFan Sahin
Department of Cardiology, Bağcılar Training and Research Hospital, University of Health Sciences, 34200 Istanbul, Türkiye
2 shared publications - Kamil Gulsen
Department of Cardiology, Faculty of Medicine, Near East University; Nicosia-Turkish Republic of Northern Cyprus
2 shared publications - Murat Ziyrek
Department of Cardiology, Farabi Hospital, Konya
2 shared publications
Latest Publications
- Open Access
Amplitude of the V1-R Wave Predicts Survival After Transcatheter Aortic Valve Replacement
Background and Objectives: The function of the right heart and the pulmonary artery pressure have been linked to outcomes following transcatheter aortic valve replacement (TAVR). This study utilized the V1-R wave amplitude from pre-procedural electrocardiography as an indicator of pulmonary artery pressure, examining its connection to one-year mortality post-TAVR. Materials and Methods: This retrospective study, conducted at a single center, involved patients with severe symptomatic aortic valve stenosis who underwent TAVR between March 2014 and September 2023. The study analyzed patients’ pre-procedural V1-R wave amplitude on electrocardiography and systolic pulmonary artery pressure measured by transthoracic echocardiography. Patients who died within one year were classified as non-survivors; others as survivors. Results: Of the 236 patients, 56 (23.7%) died within one year of follow-up. A cut-off value of 66.5 µV for V1-R wave amplitude was associated with 66.1% sensitivity and 66.7% specificity (AUC: 0.735; 95% CI: 0.660–0.811), and 55.5 mmHg for systolic pulmonary artery pressure (sPAP) was associated with 67.9% sensitivity and 68.3% specificity (AUC: 0.708; 95% CI: 0.624–0.793) in predicting one-year mortality. The independent predictors of increased mortality included a history of cerebrovascular disease, elevated sPAP, and a high R-wave amplitude in lead V1. In contrast, statin use emerged as an independent predictor of reduced mortality. Conclusions: The V1-R wave amplitude and sPAP measured before TAVR were independent predictors of mortality following TAVR, highlighting the significance of right heart function.
Open AccessAmplitude of the V1-R Wave Predicts Survival After Transcatheter Aortic Valve Replacement
Background and Objectives: The function of the right heart and the pulmonary artery pressure have been linked to outcomes following transcatheter aortic valve replacement (TAVR). This study utilized the V1-R wave amplitude from pre-procedural electrocardiography as an indicator of pulmonary artery pressure, examining its connection to one-year mortality post-TAVR. Materials and Methods: This retrospective study, conducted at a single center, involved patients with severe symptomatic aortic valve stenosis who underwent TAVR between March 2014 and September 2023. The study analyzed patients’ pre-procedural V1-R wave amplitude on electrocardiography and systolic pulmonary artery pressure measured by transthoracic echocardiography. Patients who died within one year were classified as non-survivors; others as survivors. Results: Of the 236 patients, 56 (23.7%) died within one year of follow-up. A cut-off value of 66.5 µV for V1-R wave amplitude was associated with 66.1% sensitivity and 66.7% specificity (AUC: 0.735; 95% CI: 0.660–0.811), and 55.5 mmHg for systolic pulmonary artery pressure (sPAP) was associated with 67.9% sensitivity and 68.3% specificity (AUC: 0.708; 95% CI: 0.624–0.793) in predicting one-year mortality. The independent predictors of increased mortality included a history of cerebrovascular disease, elevated sPAP, and a high R-wave amplitude in lead V1. In contrast, statin use emerged as an independent predictor of reduced mortality. Conclusions: The V1-R wave amplitude and sPAP measured before TAVR were independent predictors of mortality following TAVR, highlighting the significance of right heart function.
- Open Access
- 1 January 2024
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 28 (5) , 260-262
Reply to Letter to the Editor: “Reevaluating the Case of an Allegedly Absent Circumflex Artery: A Detailed Analysis of İnce et al.’s Report”
- 1 January 2024
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 28 (5) , 260-262
Open AccessReply to Letter to the Editor: “Reevaluating the Case of an Allegedly Absent Circumflex Artery: A Detailed Analysis of İnce et al.’s Report”
- 30 April 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (7) , 803-810
Effect of SGLT‐2 inhibitors as an add‐on therapy to metformin on P wave indices and atrial electromechanics in type 2 diabetes mellitus patients
Introduction: Sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors have been shown to reduce the risk of atrial fibrillation (AF) occurrence in patients with diabetes mellitus (DM). In this prospective study, we aimed to analyze the effect of SGLT‐2 inhibitors as an add‐on therapy to metformin on P wave indices and atrial electromechanics in patients with type 2 DM.Methods: A total of 144 patients enrolled. Electrocardiographic indices were recorded on admission and at 3rd and 6th month of the combination therapy. P wave indices and atrial electromechanical coupling intervals were measured and compared.Results: Although decrease in P wave dispersion (62.78 ± 9.59 vs. 53.62 ± 10.65; p = .002) became significant at 6th month of combination therapy, significant decreases in P wave terminal force in V1 (37.79 ± 3.45 vs. 32.01 ± 5.74; p = .035), left atrial volume index (35.87 ± 6.57 vs. 31.33 ± 7.31; p = .042), left sided intra‐atrial electromechanical delay (32.09 ± 9.17 vs. 27.61 ± 8.50; p = .016), right sided intra‐atrial electromechanical delay (31.82 ± 4.92 vs. 27.65 ± 8.05; p = .042), and interatrial electromechanical delay (29.65 ± 7.52 vs. 25.96 ± 4.30; p = .044) were seen as early as 3rd month of treatment. Besides, there was no statistically significant difference between Empagliflozin and Dapagliflozin subgroups in terms of mentioned parameters.Conclusion: SGLT‐2 inhibitors as an add‐on therapy to metformin were shown to significantly improve P wave indices and atrial electromechanics in type 2 DM patients as early as the 3rd month of treatment. It was thought that this may be one of the underlying mechanisms of the decrease in the frequency of AF with the use of SGLT2 inhibitors.
- 30 April 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (7) , 803-810
Effect of SGLT‐2 inhibitors as an add‐on therapy to metformin on P wave indices and atrial electromechanics in type 2 diabetes mellitus patients
Introduction: Sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors have been shown to reduce the risk of atrial fibrillation (AF) occurrence in patients with diabetes mellitus (DM). In this prospective study, we aimed to analyze the effect of SGLT‐2 inhibitors as an add‐on therapy to metformin on P wave indices and atrial electromechanics in patients with type 2 DM.Methods: A total of 144 patients enrolled. Electrocardiographic indices were recorded on admission and at 3rd and 6th month of the combination therapy. P wave indices and atrial electromechanical coupling intervals were measured and compared.Results: Although decrease in P wave dispersion (62.78 ± 9.59 vs. 53.62 ± 10.65; p = .002) became significant at 6th month of combination therapy, significant decreases in P wave terminal force in V1 (37.79 ± 3.45 vs. 32.01 ± 5.74; p = .035), left atrial volume index (35.87 ± 6.57 vs. 31.33 ± 7.31; p = .042), left sided intra‐atrial electromechanical delay (32.09 ± 9.17 vs. 27.61 ± 8.50; p = .016), right sided intra‐atrial electromechanical delay (31.82 ± 4.92 vs. 27.65 ± 8.05; p = .042), and interatrial electromechanical delay (29.65 ± 7.52 vs. 25.96 ± 4.30; p = .044) were seen as early as 3rd month of treatment. Besides, there was no statistically significant difference between Empagliflozin and Dapagliflozin subgroups in terms of mentioned parameters.Conclusion: SGLT‐2 inhibitors as an add‐on therapy to metformin were shown to significantly improve P wave indices and atrial electromechanics in type 2 DM patients as early as the 3rd month of treatment. It was thought that this may be one of the underlying mechanisms of the decrease in the frequency of AF with the use of SGLT2 inhibitors.
- 1 December 2022
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 7 (4) , 357-353
Outcomes of Hospitalized Patients with Infective Endocarditis: A Tertiary Center Experience
- 1 December 2022
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 7 (4) , 357-353
Outcomes of Hospitalized Patients with Infective Endocarditis: A Tertiary Center Experience
- 14 April 2022
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 7 (1) , 32-37
The Role of MPV-to-Lymphocyte Ratio and MPVto- Platelet Ratio in Predicting Mortality in Patients with Acute Myocardial Infarction
- 14 April 2022
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 7 (1) , 32-37
The Role of MPV-to-Lymphocyte Ratio and MPVto- Platelet Ratio in Predicting Mortality in Patients with Acute Myocardial Infarction
- 8 December 2020
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 5 (4) , 148-151
Clinical Significance of Cardiac Permanent Pacemaker Mode Option in Patients with Complete Atrioventricular Block
- 8 December 2020
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 5 (4) , 148-151
Clinical Significance of Cardiac Permanent Pacemaker Mode Option in Patients with Complete Atrioventricular Block